Regeneron Pharmaceuticals and Class Action Insights
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has recently found itself at the center of a class action lawsuit that brings forth significant concerns for its shareholders. If you have invested in Regeneron during the defined class period, it's essential to understand your rights and the implications of this ongoing legal situation.
Understanding the Class Action Lawsuit
The lawsuit revolves around allegations that Regeneron made misleading statements and failed to disclose crucial information regarding its business practices, particularly involving its popular product, Eylea. Shareholders who purchased shares of REGN from November 2, 2023, to October 30, 2024, are encouraged to explore their eligibility for becoming a lead plaintiff in this case. Being a lead plaintiff isn't necessary to pursue any potential recovery.
Allegations Against Regeneron
What Are the Key Allegations?
The core of the complaint asserts that during the class period, Regeneron engaged in practices that misled investors. Notably, the firm allegedly covered credit card fees for distributors, which in turn subsidized the prices charged to customers using credit cards for Eylea. These actions purportedly led to a distortion in the real pricing structure of Eylea and provided a false representation of the company's sales figures.
Potential Consequences
As the lawsuit unfolds, it's claimed that by not disclosing credit card fee payments as price concessions, Regeneron misrepresented important information to federal agencies, thus violating the False Claims Act. This misrepresentation may have led to inflated stock prices, giving investors a false sense of security about the company's health and operations.
Important Deadlines
Investors should not overlook the crucial lead plaintiff deadline of March 10, 2025. Prompt action may be vital for those wishing to assert their involvement and seek recovery through this class action. Shareholders are advised to register their information as soon as possible to stay updated.
Next Steps for Shareholders
When shareholders register their participation in this class action, they will gain access to a portfolio monitoring tool. This feature will keep them informed of case progress and any significant developments throughout the legal process. There are no fees attached to this registration, ensuring participation is seamless and obligation-free.
Why Choose The Gross Law Firm?
The Gross Law Firm is recognized nationally for its dedication to protecting investors' rights. Their mission is to hold companies accountable for fraudulent and illegal business practices. By pursuing recovery for those affected by misleading statements or omissions, they advocate for a fair and just market environment. They stand firm for all investors who have been misled and seek to restore confidence in equitable business conduct.
Contact Information
If you would like to learn more about this class action or have any inquiries, you can contact The Gross Law Firm at their office located at 15 West 38th Street, 12th floor, New York, NY, 10018. They can be reached by phone at (646) 453-8903, where you can obtain further details on how to proceed with your claim.
Frequently Asked Questions
What is the class action lawsuit against Regeneron about?
The lawsuit alleges that Regeneron misled investors by failing to disclose critical information about their pricing policies and sales practices related to Eylea.
Who is eligible to participate in the lawsuit?
Shareholders who purchased REGN shares from November 2, 2023, to October 30, 2024, are eligible to participate in the class action.
What is the deadline to register as a lead plaintiff?
The deadline to seek lead plaintiff status is March 10, 2025.
Is there a cost for shareholders to join the class action?
No, there is no cost or obligation for shareholders to participate in the class action.
Why choose The Gross Law Firm?
The Gross Law Firm has a reputation for advocating on behalf of investors who have suffered from deceit and illegal practices, working diligently to ensure justice is served.
